Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DRRX 
Durect Corporation (DRRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/10/2025: DRRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.5
1 Year Target Price $2.5
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.96% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 59.31M USD | Price to earnings Ratio - | 1Y Target Price 2.5 |
Price to earnings Ratio - | 1Y Target Price 2.5 | ||
Volume (30-day avg) 3 | Beta 0.93 | 52 Weeks Range 0.48 - 2.64 | Updated Date 09/14/2025 |
52 Weeks Range 0.48 - 2.64 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -209.9% | Operating Margin (TTM) -627.07% |
Management Effectiveness
Return on Assets (TTM) -45.34% | Return on Equity (TTM) -307.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 54561497 | Price to Sales(TTM) 35.8 |
Enterprise Value 54561497 | Price to Sales(TTM) 35.8 | ||
Enterprise Value to Revenue 32.93 | Enterprise Value to EBITDA -2.48 | Shares Outstanding 31054200 | Shares Floating 26469657 |
Shares Outstanding 31054200 | Shares Floating 26469657 | ||
Percent Insiders 12.67 | Percent Institutions 23.57 |
Upturn AI SWOT
Durect Corporation
Company Overview
History and Background
Durect Corporation was founded in 1998. The company focuses on developing novel and proprietary therapeutics for chronic diseases and acute conditions.
Core Business Areas
- Drug Delivery Technologies: Durect develops and manufactures sustained-release drug delivery systems.
- Pharmaceutical Development: The company develops its own proprietary pharmaceutical products, often leveraging its drug delivery technologies.
Leadership and Structure
James E. Brown is the President and CEO. The company operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- ALZET Osmotic Pumps: These are small, implantable pumps used for continuous drug delivery in research. Revenue generated from this product is confidential and the exact market share is unknown. Competitors include Smiths Medical and Medtronic (MDT).
- POSIMIR: A post-operative pain relief depot indicated for direct administration into the surgical site to manage post-surgical pain for up to 72 hours. This product is licensed. Competitors are generic pain medications, and alternatives like opioids and NSAIDs.
- ORADUR technology: An oral drug delivery system. Revenue generated from this product is confidential and the exact market share is unknown.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, characterized by continuous innovation and development of new therapies.
Positioning
Durect is positioned as a specialty pharmaceutical company focused on drug delivery technologies and niche therapeutics.
Total Addressable Market (TAM)
The TAM for controlled-release drug delivery systems is substantial. Exact TAM is difficult to define because it depends upon the specific therapeutic areas and product targets. Durect occupies a small segment of the drug delivery space.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technologies
- Established partnerships
- Experienced management team
Weaknesses
- Limited product pipeline
- Dependence on partners for revenue
- History of net losses
Opportunities
- Expansion into new therapeutic areas
- Development of new drug delivery platforms
- Increased demand for sustained-release medications
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent expiration
Competitors and Market Share
Key Competitors
- PACB
- XOMA
- VTVT
Competitive Landscape
Durect faces competition from larger pharmaceutical companies with more resources. Their competitive advantage lies in their specialized drug delivery technologies and the development of niche products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been sporadic, dependent on licensing agreements and product development progress.
Future Projections: Future growth relies on clinical trial outcomes, partnerships, and regulatory approvals for their products
Recent Initiatives: Focus on their activities with their existing products such as POSIMIR and ALZET and their drug delivery technologies like ORADUR
Summary
Durect Corporation specializes in drug delivery technologies and has potential for growth. Its strategic partnerships are a plus, but the company has experienced net losses in the past, faces stiff competition, and depends greatly on third-party success. Further success hinges on successful clinical trials, regulatory approvals, and expanding its product pipeline. Durect needs to focus on profitability and reducing its dependence on external partners.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Durect Corporation Investor Relations
- SEC Filings
- Various Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Financial data should be verified with official company documents.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Durect Corporation
Exchange NASDAQ | Headquaters Cupertino, CA, United States | ||
IPO Launch date 2000-09-28 | Co-Founder, CEO, President & Director Dr. James E. Brown D.V.M. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 13 | Website https://www.durect.com |
Full time employees 13 | Website https://www.durect.com | ||
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. As of September 11, 2025, DURECT Corporation operates as a subsidiary of Bausch Health Americas, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.